Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

Page: 113

Published Date: 20 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

The global Community-acquired Bacterial Pneumonia market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

This report studies the global Community-acquired Bacterial Pneumonia demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Community-acquired Bacterial Pneumonia, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Community-acquired Bacterial Pneumonia that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Community-acquired Bacterial Pneumonia total market, 2018-2029, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Community-acquired Bacterial Pneumonia total market, key domestic companies and share, (USD Million)
Global Community-acquired Bacterial Pneumonia revenue by player and market share 2018-2023, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by Type, CAGR, 2018-2029, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Community-acquired Bacterial Pneumonia market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Community-acquired Bacterial Pneumonia market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Community-acquired Bacterial Pneumonia Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Community-acquired Bacterial Pneumonia Market, Segmentation by Type
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others

Global Community-acquired Bacterial Pneumonia Market, Segmentation by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Companies Profiled:
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

Key Questions Answered
1. How big is the global Community-acquired Bacterial Pneumonia market?
2. What is the demand of the global Community-acquired Bacterial Pneumonia market?
3. What is the year over year growth of the global Community-acquired Bacterial Pneumonia market?
4. What is the total value of the global Community-acquired Bacterial Pneumonia market?
5. Who are the major players in the global Community-acquired Bacterial Pneumonia market?
6. What are the growth factors driving the market demand?
btl

Table of Contents

1 Supply Summary
1.1 Community-acquired Bacterial Pneumonia Introduction
1.2 World Community-acquired Bacterial Pneumonia Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Community-acquired Bacterial Pneumonia Total Market by Region (by Headquarter Location)
1.3.1 World Community-acquired Bacterial Pneumonia Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.3 China Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.4 Europe Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.5 Japan Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.6 South Korea Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.7 ASEAN Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.8 India Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Community-acquired Bacterial Pneumonia Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Community-acquired Bacterial Pneumonia Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
2.1 World Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.2 World Community-acquired Bacterial Pneumonia Consumption Value by Region
2.2.1 World Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2023)
2.2.2 World Community-acquired Bacterial Pneumonia Consumption Value Forecast by Region (2024-2029)
2.3 United States Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.4 China Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.5 Europe Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.6 Japan Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.7 South Korea Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.8 ASEAN Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.9 India Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)

3 World Community-acquired Bacterial Pneumonia Companies Competitive Analysis
3.1 World Community-acquired Bacterial Pneumonia Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Community-acquired Bacterial Pneumonia Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Community-acquired Bacterial Pneumonia in 2022
3.2.3 Global Concentration Ratios (CR8) for Community-acquired Bacterial Pneumonia in 2022
3.3 Community-acquired Bacterial Pneumonia Company Evaluation Quadrant
3.4 Community-acquired Bacterial Pneumonia Market: Overall Company Footprint Analysis
3.4.1 Community-acquired Bacterial Pneumonia Market: Region Footprint
3.4.2 Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
3.4.3 Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
4.1 United States VS China: Community-acquired Bacterial Pneumonia Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Community-acquired Bacterial Pneumonia Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Community-acquired Bacterial Pneumonia Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Community-acquired Bacterial Pneumonia Consumption Value Comparison
4.2.1 United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Community-acquired Bacterial Pneumonia Companies and Market Share, 2018-2023
4.3.1 United States Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023)
4.4 China Based Companies Community-acquired Bacterial Pneumonia Revenue and Market Share, 2018-2023
4.4.1 China Based Community-acquired Bacterial Pneumonia Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023)
4.5 Rest of World Based Community-acquired Bacterial Pneumonia Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023)

5 Market Analysis by Type
5.1 World Community-acquired Bacterial Pneumonia Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Pleuromutilin Antibiotic
5.2.2 Cephalosporin
5.2.3 Glycylcycline
5.2.4 Oxazolidinone
5.2.5 Ketolide
5.2.6 Others
5.3 Market Segment by Type
5.3.1 World Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
5.3.2 World Community-acquired Bacterial Pneumonia Market Size by Type (2024-2029)
5.3.3 World Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
6.1 World Community-acquired Bacterial Pneumonia Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Segment by Application
6.3.1 World Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
6.3.2 World Community-acquired Bacterial Pneumonia Market Size by Application (2024-2029)
6.3.3 World Community-acquired Bacterial Pneumonia Market Size by Application (2018-2029)

7 Company Profiles
7.1 Nabriva Therapeutics
7.1.1 Nabriva Therapeutics Details
7.1.2 Nabriva Therapeutics Major Business
7.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Services
7.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Nabriva Therapeutics Recent Developments/Updates
7.1.6 Nabriva Therapeutics Competitive Strengths & Weaknesses
7.2 Paratek Pharmaceuticals
7.2.1 Paratek Pharmaceuticals Details
7.2.2 Paratek Pharmaceuticals Major Business
7.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
7.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Paratek Pharmaceuticals Recent Developments/Updates
7.2.6 Paratek Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Melinta Therapeutics
7.3.1 Melinta Therapeutics Details
7.3.2 Melinta Therapeutics Major Business
7.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Services
7.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Melinta Therapeutics Recent Developments/Updates
7.3.6 Melinta Therapeutics Competitive Strengths & Weaknesses
7.4 Allergan plc
7.4.1 Allergan plc Details
7.4.2 Allergan plc Major Business
7.4.3 Allergan plc Community-acquired Bacterial Pneumonia Product and Services
7.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Allergan plc Recent Developments/Updates
7.4.6 Allergan plc Competitive Strengths & Weaknesses
7.5 Bayer AG
7.5.1 Bayer AG Details
7.5.2 Bayer AG Major Business
7.5.3 Bayer AG Community-acquired Bacterial Pneumonia Product and Services
7.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Bayer AG Recent Developments/Updates
7.5.6 Bayer AG Competitive Strengths & Weaknesses
7.6 Lupin Pharmaceuticals
7.6.1 Lupin Pharmaceuticals Details
7.6.2 Lupin Pharmaceuticals Major Business
7.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
7.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Lupin Pharmaceuticals Recent Developments/Updates
7.6.6 Lupin Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Mylan N.V.
7.7.1 Mylan N.V. Details
7.7.2 Mylan N.V. Major Business
7.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Product and Services
7.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Mylan N.V. Recent Developments/Updates
7.7.6 Mylan N.V. Competitive Strengths & Weaknesses
7.8 Sanofi S.A.
7.8.1 Sanofi S.A. Details
7.8.2 Sanofi S.A. Major Business
7.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Services
7.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Sanofi S.A. Recent Developments/Updates
7.8.6 Sanofi S.A. Competitive Strengths & Weaknesses
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Details
7.9.2 Pfizer Inc. Major Business
7.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Services
7.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Inc. Recent Developments/Updates
7.9.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.10 Dainippon Sumitomo Pharma
7.10.1 Dainippon Sumitomo Pharma Details
7.10.2 Dainippon Sumitomo Pharma Major Business
7.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Services
7.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Dainippon Sumitomo Pharma Recent Developments/Updates
7.10.6 Dainippon Sumitomo Pharma Competitive Strengths & Weaknesses
7.11 Takeda Pharmaceutical Company Limited
7.11.1 Takeda Pharmaceutical Company Limited Details
7.11.2 Takeda Pharmaceutical Company Limited Major Business
7.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Services
7.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
7.11.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
7.12 Basilea Pharmaceutica International AG
7.12.1 Basilea Pharmaceutica International AG Details
7.12.2 Basilea Pharmaceutica International AG Major Business
7.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Services
7.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Basilea Pharmaceutica International AG Recent Developments/Updates
7.12.6 Basilea Pharmaceutica International AG Competitive Strengths & Weaknesses

8 Industry Chain Analysis
8.1 Community-acquired Bacterial Pneumonia Industry Chain
8.2 Community-acquired Bacterial Pneumonia Upstream Analysis
8.3 Community-acquired Bacterial Pneumonia Midstream Analysis
8.4 Community-acquired Bacterial Pneumonia Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. World Community-acquired Bacterial Pneumonia Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Community-acquired Bacterial Pneumonia Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Community-acquired Bacterial Pneumonia Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Community-acquired Bacterial Pneumonia Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Community-acquired Bacterial Pneumonia Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Community-acquired Bacterial Pneumonia Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Community-acquired Bacterial Pneumonia Players in 2022
Table 12. World Community-acquired Bacterial Pneumonia Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Community-acquired Bacterial Pneumonia Company Evaluation Quadrant
Table 14. Head Office of Key Community-acquired Bacterial Pneumonia Player
Table 15. Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
Table 16. Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
Table 17. Community-acquired Bacterial Pneumonia Mergers & Acquisitions Activity
Table 18. United States VS China Community-acquired Bacterial Pneumonia Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Community-acquired Bacterial Pneumonia Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
Table 21. United States Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2018-2023)
Table 23. China Based Community-acquired Bacterial Pneumonia Companies, Headquarters (Province, Country)
Table 24. China Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2018-2023)
Table 26. Rest of World Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2018-2023)
Table 29. World Community-acquired Bacterial Pneumonia Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & (USD Million)
Table 31. World Community-acquired Bacterial Pneumonia Market Size by Type (2024-2029) & (USD Million)
Table 32. World Community-acquired Bacterial Pneumonia Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & (USD Million)
Table 34. World Community-acquired Bacterial Pneumonia Market Size by Application (2024-2029) & (USD Million)
Table 35. Nabriva Therapeutics Basic Information, Area Served and Competitors
Table 36. Nabriva Therapeutics Major Business
Table 37. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Services
Table 38. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Nabriva Therapeutics Recent Developments/Updates
Table 40. Nabriva Therapeutics Competitive Strengths & Weaknesses
Table 41. Paratek Pharmaceuticals Basic Information, Area Served and Competitors
Table 42. Paratek Pharmaceuticals Major Business
Table 43. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
Table 44. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Paratek Pharmaceuticals Recent Developments/Updates
Table 46. Paratek Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Melinta Therapeutics Basic Information, Area Served and Competitors
Table 48. Melinta Therapeutics Major Business
Table 49. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Services
Table 50. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Melinta Therapeutics Recent Developments/Updates
Table 52. Melinta Therapeutics Competitive Strengths & Weaknesses
Table 53. Allergan plc Basic Information, Area Served and Competitors
Table 54. Allergan plc Major Business
Table 55. Allergan plc Community-acquired Bacterial Pneumonia Product and Services
Table 56. Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Allergan plc Recent Developments/Updates
Table 58. Allergan plc Competitive Strengths & Weaknesses
Table 59. Bayer AG Basic Information, Area Served and Competitors
Table 60. Bayer AG Major Business
Table 61. Bayer AG Community-acquired Bacterial Pneumonia Product and Services
Table 62. Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Bayer AG Recent Developments/Updates
Table 64. Bayer AG Competitive Strengths & Weaknesses
Table 65. Lupin Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Lupin Pharmaceuticals Major Business
Table 67. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
Table 68. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Lupin Pharmaceuticals Recent Developments/Updates
Table 70. Lupin Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Mylan N.V. Basic Information, Area Served and Competitors
Table 72. Mylan N.V. Major Business
Table 73. Mylan N.V. Community-acquired Bacterial Pneumonia Product and Services
Table 74. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Mylan N.V. Recent Developments/Updates
Table 76. Mylan N.V. Competitive Strengths & Weaknesses
Table 77. Sanofi S.A. Basic Information, Area Served and Competitors
Table 78. Sanofi S.A. Major Business
Table 79. Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Services
Table 80. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Sanofi S.A. Recent Developments/Updates
Table 82. Sanofi S.A. Competitive Strengths & Weaknesses
Table 83. Pfizer Inc. Basic Information, Area Served and Competitors
Table 84. Pfizer Inc. Major Business
Table 85. Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Services
Table 86. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Inc. Recent Developments/Updates
Table 88. Pfizer Inc. Competitive Strengths & Weaknesses
Table 89. Dainippon Sumitomo Pharma Basic Information, Area Served and Competitors
Table 90. Dainippon Sumitomo Pharma Major Business
Table 91. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Services
Table 92. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Dainippon Sumitomo Pharma Recent Developments/Updates
Table 94. Dainippon Sumitomo Pharma Competitive Strengths & Weaknesses
Table 95. Takeda Pharmaceutical Company Limited Basic Information, Area Served and Competitors
Table 96. Takeda Pharmaceutical Company Limited Major Business
Table 97. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Services
Table 98. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 100. Basilea Pharmaceutica International AG Basic Information, Area Served and Competitors
Table 101. Basilea Pharmaceutica International AG Major Business
Table 102. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Services
Table 103. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 104. Global Key Players of Community-acquired Bacterial Pneumonia Upstream (Raw Materials)
Table 105. Community-acquired Bacterial Pneumonia Typical Customers
List of Figure
Figure 1. Community-acquired Bacterial Pneumonia Picture
Figure 2. World Community-acquired Bacterial Pneumonia Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Community-acquired Bacterial Pneumonia Total Market Size (2018-2029) & (USD Million)
Figure 4. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 13. Community-acquired Bacterial Pneumonia Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 16. World Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 18. China Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 23. India Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Community-acquired Bacterial Pneumonia by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Community-acquired Bacterial Pneumonia Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Community-acquired Bacterial Pneumonia Markets in 2022
Figure 27. United States VS China: Community-acquired Bacterial Pneumonia Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Community-acquired Bacterial Pneumonia Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2022
Figure 31. Pleuromutilin Antibiotic
Figure 32. Cephalosporin
Figure 33. Glycylcycline
Figure 34. Oxazolidinone
Figure 35. Ketolide
Figure 36. Others
Figure 37. World Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2029)
Figure 38. World Community-acquired Bacterial Pneumonia Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 39. World Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2022
Figure 40. Hospital Pharmacies
Figure 41. Retail Pharmacies
Figure 42. Online Pharmacies
Figure 43. Community-acquired Bacterial Pneumonia Industrial Chain
Figure 44. Methodology
Figure 45. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

Global Community-acquired Bacterial Pneumonia Supply, Demand and Key Producers, 2023-2029

Page: 113

Published Date: 20 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

The global Community-acquired Bacterial Pneumonia market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.

This report studies the global Community-acquired Bacterial Pneumonia demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Community-acquired Bacterial Pneumonia, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Community-acquired Bacterial Pneumonia that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Community-acquired Bacterial Pneumonia total market, 2018-2029, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Community-acquired Bacterial Pneumonia total market, key domestic companies and share, (USD Million)
Global Community-acquired Bacterial Pneumonia revenue by player and market share 2018-2023, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by Type, CAGR, 2018-2029, (USD Million)
Global Community-acquired Bacterial Pneumonia total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Community-acquired Bacterial Pneumonia market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nabriva Therapeutics, Paratek Pharmaceuticals, Melinta Therapeutics, Allergan plc, Bayer AG, Lupin Pharmaceuticals, Mylan N.V., Sanofi S.A. and Pfizer Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Community-acquired Bacterial Pneumonia market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Community-acquired Bacterial Pneumonia Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Community-acquired Bacterial Pneumonia Market, Segmentation by Type
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others

Global Community-acquired Bacterial Pneumonia Market, Segmentation by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Companies Profiled:
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

Key Questions Answered
1. How big is the global Community-acquired Bacterial Pneumonia market?
2. What is the demand of the global Community-acquired Bacterial Pneumonia market?
3. What is the year over year growth of the global Community-acquired Bacterial Pneumonia market?
4. What is the total value of the global Community-acquired Bacterial Pneumonia market?
5. Who are the major players in the global Community-acquired Bacterial Pneumonia market?
6. What are the growth factors driving the market demand?
btl

Table of Contents

1 Supply Summary
1.1 Community-acquired Bacterial Pneumonia Introduction
1.2 World Community-acquired Bacterial Pneumonia Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Community-acquired Bacterial Pneumonia Total Market by Region (by Headquarter Location)
1.3.1 World Community-acquired Bacterial Pneumonia Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.3 China Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.4 Europe Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.5 Japan Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.6 South Korea Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.7 ASEAN Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.3.8 India Community-acquired Bacterial Pneumonia Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Community-acquired Bacterial Pneumonia Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Community-acquired Bacterial Pneumonia Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
2.1 World Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.2 World Community-acquired Bacterial Pneumonia Consumption Value by Region
2.2.1 World Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2023)
2.2.2 World Community-acquired Bacterial Pneumonia Consumption Value Forecast by Region (2024-2029)
2.3 United States Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.4 China Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.5 Europe Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.6 Japan Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.7 South Korea Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.8 ASEAN Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)
2.9 India Community-acquired Bacterial Pneumonia Consumption Value (2018-2029)

3 World Community-acquired Bacterial Pneumonia Companies Competitive Analysis
3.1 World Community-acquired Bacterial Pneumonia Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Community-acquired Bacterial Pneumonia Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Community-acquired Bacterial Pneumonia in 2022
3.2.3 Global Concentration Ratios (CR8) for Community-acquired Bacterial Pneumonia in 2022
3.3 Community-acquired Bacterial Pneumonia Company Evaluation Quadrant
3.4 Community-acquired Bacterial Pneumonia Market: Overall Company Footprint Analysis
3.4.1 Community-acquired Bacterial Pneumonia Market: Region Footprint
3.4.2 Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
3.4.3 Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
4.1 United States VS China: Community-acquired Bacterial Pneumonia Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Community-acquired Bacterial Pneumonia Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Community-acquired Bacterial Pneumonia Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Community-acquired Bacterial Pneumonia Consumption Value Comparison
4.2.1 United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Community-acquired Bacterial Pneumonia Companies and Market Share, 2018-2023
4.3.1 United States Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023)
4.4 China Based Companies Community-acquired Bacterial Pneumonia Revenue and Market Share, 2018-2023
4.4.1 China Based Community-acquired Bacterial Pneumonia Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023)
4.5 Rest of World Based Community-acquired Bacterial Pneumonia Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023)

5 Market Analysis by Type
5.1 World Community-acquired Bacterial Pneumonia Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Pleuromutilin Antibiotic
5.2.2 Cephalosporin
5.2.3 Glycylcycline
5.2.4 Oxazolidinone
5.2.5 Ketolide
5.2.6 Others
5.3 Market Segment by Type
5.3.1 World Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023)
5.3.2 World Community-acquired Bacterial Pneumonia Market Size by Type (2024-2029)
5.3.3 World Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
6.1 World Community-acquired Bacterial Pneumonia Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Segment by Application
6.3.1 World Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023)
6.3.2 World Community-acquired Bacterial Pneumonia Market Size by Application (2024-2029)
6.3.3 World Community-acquired Bacterial Pneumonia Market Size by Application (2018-2029)

7 Company Profiles
7.1 Nabriva Therapeutics
7.1.1 Nabriva Therapeutics Details
7.1.2 Nabriva Therapeutics Major Business
7.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Services
7.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Nabriva Therapeutics Recent Developments/Updates
7.1.6 Nabriva Therapeutics Competitive Strengths & Weaknesses
7.2 Paratek Pharmaceuticals
7.2.1 Paratek Pharmaceuticals Details
7.2.2 Paratek Pharmaceuticals Major Business
7.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
7.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Paratek Pharmaceuticals Recent Developments/Updates
7.2.6 Paratek Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Melinta Therapeutics
7.3.1 Melinta Therapeutics Details
7.3.2 Melinta Therapeutics Major Business
7.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Services
7.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Melinta Therapeutics Recent Developments/Updates
7.3.6 Melinta Therapeutics Competitive Strengths & Weaknesses
7.4 Allergan plc
7.4.1 Allergan plc Details
7.4.2 Allergan plc Major Business
7.4.3 Allergan plc Community-acquired Bacterial Pneumonia Product and Services
7.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Allergan plc Recent Developments/Updates
7.4.6 Allergan plc Competitive Strengths & Weaknesses
7.5 Bayer AG
7.5.1 Bayer AG Details
7.5.2 Bayer AG Major Business
7.5.3 Bayer AG Community-acquired Bacterial Pneumonia Product and Services
7.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Bayer AG Recent Developments/Updates
7.5.6 Bayer AG Competitive Strengths & Weaknesses
7.6 Lupin Pharmaceuticals
7.6.1 Lupin Pharmaceuticals Details
7.6.2 Lupin Pharmaceuticals Major Business
7.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
7.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Lupin Pharmaceuticals Recent Developments/Updates
7.6.6 Lupin Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Mylan N.V.
7.7.1 Mylan N.V. Details
7.7.2 Mylan N.V. Major Business
7.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Product and Services
7.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Mylan N.V. Recent Developments/Updates
7.7.6 Mylan N.V. Competitive Strengths & Weaknesses
7.8 Sanofi S.A.
7.8.1 Sanofi S.A. Details
7.8.2 Sanofi S.A. Major Business
7.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Services
7.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Sanofi S.A. Recent Developments/Updates
7.8.6 Sanofi S.A. Competitive Strengths & Weaknesses
7.9 Pfizer Inc.
7.9.1 Pfizer Inc. Details
7.9.2 Pfizer Inc. Major Business
7.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Services
7.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Pfizer Inc. Recent Developments/Updates
7.9.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.10 Dainippon Sumitomo Pharma
7.10.1 Dainippon Sumitomo Pharma Details
7.10.2 Dainippon Sumitomo Pharma Major Business
7.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Services
7.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Dainippon Sumitomo Pharma Recent Developments/Updates
7.10.6 Dainippon Sumitomo Pharma Competitive Strengths & Weaknesses
7.11 Takeda Pharmaceutical Company Limited
7.11.1 Takeda Pharmaceutical Company Limited Details
7.11.2 Takeda Pharmaceutical Company Limited Major Business
7.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Services
7.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
7.11.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
7.12 Basilea Pharmaceutica International AG
7.12.1 Basilea Pharmaceutica International AG Details
7.12.2 Basilea Pharmaceutica International AG Major Business
7.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Services
7.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Basilea Pharmaceutica International AG Recent Developments/Updates
7.12.6 Basilea Pharmaceutica International AG Competitive Strengths & Weaknesses

8 Industry Chain Analysis
8.1 Community-acquired Bacterial Pneumonia Industry Chain
8.2 Community-acquired Bacterial Pneumonia Upstream Analysis
8.3 Community-acquired Bacterial Pneumonia Midstream Analysis
8.4 Community-acquired Bacterial Pneumonia Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. World Community-acquired Bacterial Pneumonia Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Community-acquired Bacterial Pneumonia Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Community-acquired Bacterial Pneumonia Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Community-acquired Bacterial Pneumonia Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Community-acquired Bacterial Pneumonia Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Community-acquired Bacterial Pneumonia Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Community-acquired Bacterial Pneumonia Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Community-acquired Bacterial Pneumonia Players in 2022
Table 12. World Community-acquired Bacterial Pneumonia Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Community-acquired Bacterial Pneumonia Company Evaluation Quadrant
Table 14. Head Office of Key Community-acquired Bacterial Pneumonia Player
Table 15. Community-acquired Bacterial Pneumonia Market: Company Product Type Footprint
Table 16. Community-acquired Bacterial Pneumonia Market: Company Product Application Footprint
Table 17. Community-acquired Bacterial Pneumonia Mergers & Acquisitions Activity
Table 18. United States VS China Community-acquired Bacterial Pneumonia Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Community-acquired Bacterial Pneumonia Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
Table 21. United States Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2018-2023)
Table 23. China Based Community-acquired Bacterial Pneumonia Companies, Headquarters (Province, Country)
Table 24. China Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2018-2023)
Table 26. Rest of World Based Community-acquired Bacterial Pneumonia Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Community-acquired Bacterial Pneumonia Revenue Market Share (2018-2023)
Table 29. World Community-acquired Bacterial Pneumonia Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Community-acquired Bacterial Pneumonia Market Size by Type (2018-2023) & (USD Million)
Table 31. World Community-acquired Bacterial Pneumonia Market Size by Type (2024-2029) & (USD Million)
Table 32. World Community-acquired Bacterial Pneumonia Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Community-acquired Bacterial Pneumonia Market Size by Application (2018-2023) & (USD Million)
Table 34. World Community-acquired Bacterial Pneumonia Market Size by Application (2024-2029) & (USD Million)
Table 35. Nabriva Therapeutics Basic Information, Area Served and Competitors
Table 36. Nabriva Therapeutics Major Business
Table 37. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Services
Table 38. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Nabriva Therapeutics Recent Developments/Updates
Table 40. Nabriva Therapeutics Competitive Strengths & Weaknesses
Table 41. Paratek Pharmaceuticals Basic Information, Area Served and Competitors
Table 42. Paratek Pharmaceuticals Major Business
Table 43. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
Table 44. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Paratek Pharmaceuticals Recent Developments/Updates
Table 46. Paratek Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Melinta Therapeutics Basic Information, Area Served and Competitors
Table 48. Melinta Therapeutics Major Business
Table 49. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Services
Table 50. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Melinta Therapeutics Recent Developments/Updates
Table 52. Melinta Therapeutics Competitive Strengths & Weaknesses
Table 53. Allergan plc Basic Information, Area Served and Competitors
Table 54. Allergan plc Major Business
Table 55. Allergan plc Community-acquired Bacterial Pneumonia Product and Services
Table 56. Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Allergan plc Recent Developments/Updates
Table 58. Allergan plc Competitive Strengths & Weaknesses
Table 59. Bayer AG Basic Information, Area Served and Competitors
Table 60. Bayer AG Major Business
Table 61. Bayer AG Community-acquired Bacterial Pneumonia Product and Services
Table 62. Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Bayer AG Recent Developments/Updates
Table 64. Bayer AG Competitive Strengths & Weaknesses
Table 65. Lupin Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Lupin Pharmaceuticals Major Business
Table 67. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Services
Table 68. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Lupin Pharmaceuticals Recent Developments/Updates
Table 70. Lupin Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Mylan N.V. Basic Information, Area Served and Competitors
Table 72. Mylan N.V. Major Business
Table 73. Mylan N.V. Community-acquired Bacterial Pneumonia Product and Services
Table 74. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Mylan N.V. Recent Developments/Updates
Table 76. Mylan N.V. Competitive Strengths & Weaknesses
Table 77. Sanofi S.A. Basic Information, Area Served and Competitors
Table 78. Sanofi S.A. Major Business
Table 79. Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Services
Table 80. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Sanofi S.A. Recent Developments/Updates
Table 82. Sanofi S.A. Competitive Strengths & Weaknesses
Table 83. Pfizer Inc. Basic Information, Area Served and Competitors
Table 84. Pfizer Inc. Major Business
Table 85. Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Services
Table 86. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Pfizer Inc. Recent Developments/Updates
Table 88. Pfizer Inc. Competitive Strengths & Weaknesses
Table 89. Dainippon Sumitomo Pharma Basic Information, Area Served and Competitors
Table 90. Dainippon Sumitomo Pharma Major Business
Table 91. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Services
Table 92. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Dainippon Sumitomo Pharma Recent Developments/Updates
Table 94. Dainippon Sumitomo Pharma Competitive Strengths & Weaknesses
Table 95. Takeda Pharmaceutical Company Limited Basic Information, Area Served and Competitors
Table 96. Takeda Pharmaceutical Company Limited Major Business
Table 97. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Services
Table 98. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 100. Basilea Pharmaceutica International AG Basic Information, Area Served and Competitors
Table 101. Basilea Pharmaceutica International AG Major Business
Table 102. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Services
Table 103. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 104. Global Key Players of Community-acquired Bacterial Pneumonia Upstream (Raw Materials)
Table 105. Community-acquired Bacterial Pneumonia Typical Customers
List of Figure
Figure 1. Community-acquired Bacterial Pneumonia Picture
Figure 2. World Community-acquired Bacterial Pneumonia Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Community-acquired Bacterial Pneumonia Total Market Size (2018-2029) & (USD Million)
Figure 4. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Community-acquired Bacterial Pneumonia Revenue (2018-2029) & (USD Million)
Figure 13. Community-acquired Bacterial Pneumonia Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 16. World Community-acquired Bacterial Pneumonia Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 18. China Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 23. India Community-acquired Bacterial Pneumonia Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Community-acquired Bacterial Pneumonia by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Community-acquired Bacterial Pneumonia Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Community-acquired Bacterial Pneumonia Markets in 2022
Figure 27. United States VS China: Community-acquired Bacterial Pneumonia Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Community-acquired Bacterial Pneumonia Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Community-acquired Bacterial Pneumonia Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Community-acquired Bacterial Pneumonia Market Size Market Share by Type in 2022
Figure 31. Pleuromutilin Antibiotic
Figure 32. Cephalosporin
Figure 33. Glycylcycline
Figure 34. Oxazolidinone
Figure 35. Ketolide
Figure 36. Others
Figure 37. World Community-acquired Bacterial Pneumonia Market Size Market Share by Type (2018-2029)
Figure 38. World Community-acquired Bacterial Pneumonia Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 39. World Community-acquired Bacterial Pneumonia Market Size Market Share by Application in 2022
Figure 40. Hospital Pharmacies
Figure 41. Retail Pharmacies
Figure 42. Online Pharmacies
Figure 43. Community-acquired Bacterial Pneumonia Industrial Chain
Figure 44. Methodology
Figure 45. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

jiaGou

Add To Cart

gouMai

Buy Now